Literature DB >> 20051606

Ageing, neurodegeneration and Parkinson's disease.

John V Hindle1.   

Abstract

Age is the largest risk factor for the development and progression of Parkinson's disease (PD). Ageing affects many cellular processes that predispose to neurodegeneration, and age-related changes in cellular function predispose to the pathogenesis of PD. The accumulation of age-related somatic damage combined with a failure of compensatory mechanisms may lead to an acceleration of PD with age. The formation of Lewy bodies may represent a marker for protective mechanisms against age-related dysfunction and degeneration of the nervous system. Mild parkinsonian signs may be present in older people, which are associated with reduced function. These may be due to age-related decline in dopaminergic activity, incidental Lewy body disease, degenerative pathologies (early PD and Alzheimer's disease) or vascular pathology. Ageing may affect the clinical presentation of PD with altered drug side effects, increased risk of developing dementia and an increased likelihood of admission to a nursing home. Progression of PD, including the development of dementia, and hallucinations is related to the age of the patient rather than the age of disease onset. PD may reflect a failure of the normal cellular compensatory mechanisms in vulnerable brain regions, and this vulnerability is increased by ageing. PD is one of the best examples of an age-related disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051606     DOI: 10.1093/ageing/afp223

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  108 in total

1.  Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics).

Authors:  Tomoaki Uchiki; Karen A Weikel; Wangwang Jiao; Fu Shang; Andrea Caceres; Dorota Pawlak; James T Handa; Michael Brownlee; Ram Nagaraj; Allen Taylor
Journal:  Aging Cell       Date:  2011-11-15       Impact factor: 9.304

Review 2.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 3.  Protein-thiol oxidation and cell death: regulatory role of glutaredoxins.

Authors:  Erin M G Allen; John J Mieyal
Journal:  Antioxid Redox Signal       Date:  2012-06-05       Impact factor: 8.401

4.  Spatial distribution of 5-hydroxymethyl cytosine in rat brain and temporal distribution in striatum.

Authors:  Tingting Zheng; Qing Lv; Xiaoguang Lei; Xinzhen Yin; Baorong Zhang
Journal:  Neurochem Res       Date:  2015-02-03       Impact factor: 3.996

5.  Normalization of Reverse Transcription Quantitative PCR Data During Ageing in Distinct Cerebral Structures.

Authors:  G Bruckert; D Vivien; F Docagne; B D Roussel
Journal:  Mol Neurobiol       Date:  2015-02-07       Impact factor: 5.590

Review 6.  Peroxisomes of the Brain: Distribution, Functions, and Associated Diseases.

Authors:  Rachayeeta Deb; Neha Joshi; Shirisha Nagotu
Journal:  Neurotox Res       Date:  2021-01-05       Impact factor: 3.911

7.  Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.

Authors:  Carl G Gottschalk; Malabendu Jana; Avik Roy; Dhruv R Patel; Kalipada Pahan
Journal:  J Neurosci       Date:  2021-01-29       Impact factor: 6.167

8.  Exosomes-associated neurodegeneration and progression of Parkinson's disease.

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 9.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

10.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.